American Urological Association - AUA Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer Educational Series

advertisement

Home Education AUAUniversity Live Events Educational Calendar Bladder Cancer Educational Series

AUA Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer Educational Series

Overview

Maximum of 6.0 AMA PRA Category 1 Credits

The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.

The initiative is comprised of five unique activities, including four webinars and an interactive case-study activity. Each webinar has already been broadcast live and the webcast and audio versions are now available to view at participants' convenience.

Course Director

Robert Svatek, MD

Target Audience

This activity is designed for urologists, medical oncologists, and other healthcare providers who care for patients with bladder cancer.

Activity 1: Immunotherapy: From Research to Practice

Webcast      Audio

Course Director
Robert Svatek, MD

Faculty
Joshua J. Meeks, MD, PhD

Activity Goal and Learning Objectives

The goal of this knowledge-based activity is to improve clinicians' understanding of the relevance of immunotherapy and to increase their confidence in the clinical application of these therapies based on current evidence.

At the completion of this activity, the learner will be able to:

  1. Restate the role of the immune system in cancer prevention and elimination.
  2. Explain the function of the PD-1 and CTLA-4 pathways in the suppression of T cell activity.
  3. Discuss the effects of immune system checkpoint inhibitors on the immunosuppressive activity of tumor cells.
  4. Recognize the antitumor effects of currently available immune system checkpoint inhibitors in solid tumors.

Activity 2: Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

Webcast      Audio

Course Director
Robert Svatek, MD

Faculty
Peter Colin Black, MD
Parminder Singh, MD

Activity Goal and Learning Objectives

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events.

At the completion of this activity, the learner will be able to:

  1. Appraise clinical investigations into the efficacy of immune system checkpoint inhibitors in the treatment of bladder cancer.
  2. Describe potential drug interactions of immune system checkpoint inhibitors with other immunotherapies and chemotherapies that may improve or diminish anticancer therapeutic efficacy.
  3. Demonstrate an ability to manage side effects of immune system checkpoint inhibitors, including the recognition and response to emergent immune-related adverse effects.

Activity 3: AUA New Muscle Invasive Bladder Cancer Guideline

Webcast      Audio

Course Director
Robert Svatek, MD

Faculty
Todd Morgan, MD

Activity Goal and Learning Objectives

The goal of this knowledge-based activity is to review the new AUA guideline on Muscle Invasive Bladder Cancer. Faculty will explore the rigorous process used in the development of the evidence based guideline. This activity will provide a clinical framework for the diagnosis, evaluation, treatment and follow-up of patients with Muscle Invasive Bladder Cancer based on the best available published literature. And finally, this activity will showcase clinical scenarios in urologic practice and the correct application of the new AUA guideline in those instances.

At the completion of this activity, the learner will be able to:

  1. Analyze the latest evidence on the medical management of Muscle Invasive Bladder Cancer as outlined in the AUA guideline.
  2. Improve the diagnostic and therapeutic decision making processes by illustrating the application of the guideline in urological practice.

Activity 4: Complex Patient Cases in Bladder Cancer

Webcast      Audio

Course Director
Robert Svatek, MD

Faculty
Angela B. Smith, MD, MS

Activity Goal and Learning Objectives

The goal of this application-based activity is to review patient cases associated with the treatment of bladder cancer to assist learners apply this information into clinical practice.

At the completion of this activity, the learner will be able to:

  1. Design a comprehensive treatment plan for patients with bladder cancer that incorporates immune system checkpoint inhibitors.
  2. Prepare patients for the emergence of treatment-related adverse effects through accurate patient education.

Activity 5: AUA Clinical Problem Solving (CPS) Protocol Online Activity

Access CPS

The AUA Clinical Problem Solving Protocol is a very successful online series that is hosted on AUAUniversity. The Muscle Invasive Bladder Cancer module will be the 13th in this series and will include interactive questions with feedback.

Activity Goal and Learning Objectives

The goal of this application-based, online activity is to maximize the impact of the new AUA guideline on Muscle Invasive Bladder Cancer.

At the completion of this activity, the learner will be able to:

  1. Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline.
  2. Perform appropriate methods of evaluation and management according to the guideline.
  3. Analyze the risks and benefits for treatment according to the guideline.
  4. Integrate this AUA guideline into clinical practice.

Course Purpose

As per the National Cancer Institute, there will be an estimated 79,960 new cases of bladder cancer with an estimated 14,240 deaths in 2016.1 With a workforce of approximately 11,990 practicing urologists in the U.S., it is imperative that every urologist understand how to treat this cancer.2 The AUA survey indicated that urologists see an average of 17 patients a month with bladder cancer.3 While 84% of respondents felt very knowledgeable about the surgical treatment options, only 44% of them felt very knowledgeable about chemotherapy and immunotherapy options. Only 50% of urologists felt extremely confident in communicating to their patient or a primary caregiver about bladder cancer.

Several promising developments have recently occurred with respect to the use of agents that target immune system checkpoints. Urologists and medical oncologists must keep up with these advances and should have knowledge of all treatment options for bladder cancer including immunotherapy. Urologists, urologic-focused APNs and PAs, and medical oncologists should be prepared to manage the side effects of new and emerging immunotherapy options available to treat bladder cancer. Additionally, urologists, urologic-focused APNs and PAs, and medical oncologists should be proficient in the new AUA Non-Muscle Invasive Bladder Cancer Clinical Practice Guideline released in 2016 and the new AUA Muscle-Invasive Bladder Cancer Guideline to be released in early 2017.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30.

2. American Urological Association 2015 Census Data.

3. 2016 AUA Oncology METHODOLOGY AND STUDY PROCEDURES: The AUA Office of Education conducted research with current members of the AUA to evaluate and assess educational needs of urologists in the area of oncology. In order to assess the current educational needs of AUA members, a survey was designed by the AUA. The survey included 23 closed-ended and 2 opened questions and consisted of both clinical competency as well as knowledge-based questions. The survey was then programmed and e-mailed to a random sample of practicing urologists who are AUA members with valid emails. A total of 4,000 survey invitations were sent via e-mail. Survey invitations were sent out on March 16, 2016 and follow-up reminder e-mail invitations were sent out to those who had not completed the survey on March 24, March 29, and April 5, 2016. The survey was closed on April 6, 2016. A total of 195 surveys were completed for a total response rate of 5% and took approximately 10 minutes to complete. A total sample size of 195 is accurate within 7% at the 95% confidence level.

CME Information

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this internet live activity and enduring material for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Acknowledgements

This educational series is supported by independent educational grants from:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck

Policies

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this activity are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Questions?

Call 1-800-908-9414 or email registration@AUAnet.org.

Advertisement

Advertisement